NGEN — Nervgen Pharma Cashflow Statement
0.000.00%
Last trade - 00:00- CA$146.15m
- CA$134.69m
- 29
- 31
- 69
- 39
Annual cashflow statement for Nervgen Pharma, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -9.77 | -11.2 | -12.7 | -20.7 | -22.4 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 1.43 | 3.43 | 3.98 | 0.708 | 11.2 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.207 | 1.41 | 0.43 | 2.11 | -0.24 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -8.09 | -6.31 | -8.27 | -17.8 | -11.3 |
| Capital Expenditures | 0 | -0.003 | -0.045 | -0.021 | -0.141 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | — | — | — | 0.003 |
| Sale of Fixed Assets | |||||
| Cash from Investing Activities | 0 | -0.003 | -0.045 | -0.021 | -0.139 |
| Financing Cash Flow Items | -0.901 | -1.17 | -1.67 | -0.129 | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 9.84 | 7.85 | 19.6 | 22.6 | 0.766 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 1.63 | 1.49 | 11.3 | 5.52 | -10.8 |